Determination of the Red Cell Distribution Width, NT-proBNP and cTnT in Acute Myocardial Infarction Patients

January 11, 2023 updated by: Hemat Kamel Maarouf, Sohag University

Determination of the Relationship Between Red Cell Distribution Width, NT-proBNP and cTnT in Acute Myocardial Infarction Patients

the study is to investigate the relationship of several parameters of complete blood count (CBC) including RDW with N-terminal pro-B-type natriuretic peptide (NT-proBNP) and cardiac troponin T (cTnT) in a cohort of acute myocardial infarction (AMI) patients.

Study Overview

Status

Not yet recruiting

Conditions

Intervention / Treatment

Detailed Description

Patients and methods:

  • Type of study: Observational prospective study
  • Place of study: Sohag cardiology and gastroenterology center, department of cardiology and cardiac care unit.
  • Ethical considerations: This research will be revised by the Scientific Ethical Committee of Sohag University Hospital. Consents will be taken from all patients.

  • Study Methods:

    • A prospective study on 30 patients diagnosed as acute myocardial infarction on which measurement of CBC, serum NT-proBNP, and cTnT levels will be performed at the time of admission and by the time of discharge.

      1. Full history:

        1. Personal history: e.g. age, sex and smoking.
        2. Family history of cardiac diseases
        3. Medical history of: Hypertension, Ischemic heart disease, prior coronary artery bypass grafting, Prior Percutaneous coronary intervention, Prior Stroke, Prior Atrial fibrillation, therapeutic history
      2. Detailed clinical examination
      3. Electrocardiogram

      4. Laboratory investigation:

        1. Routine investigation in the form of CBC including RDW
        2. Specific investigation which include NT-proBNP and cTnT

Study Type

Observational

Enrollment (Anticipated)

30

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 80 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Probability Sample

Study Population

_All patients included in the study will be subjected to:

  1. Full history:

    1. Personal history: e.g. age, sex and smoking.
    2. Family history of cardiac diseases
    3. Medical history of: Hypertension, Ischemic heart disease, prior coronary artery bypass grafting, Prior Percutaneous coronary intervention, Prior Stroke, Prior Atrial fibrillation, therapeutic history
  2. Detailed clinical examination
  3. Electrocardiogram

  4. Laboratory investigation:

    1. Routine investigation in the form of CBC including RDW
    2. Specific investigation which include NT-proBNP and cTnT

Description

Inclusion Criteria:

  • patients diagnosed as acute myocardial infarction

Exclusion Criteria:

Patient with

  • Decompensated heart failure
  • Pulmonary hypertention
  • Acute pulmonary embolism
  • Septic shock

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Case-Only
  • Time Perspectives: Prospective

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
complete blood count (CBC)
Time Frame: 7 months
measurement of CBC levels will be performed
7 months
Level of (NT-proBNP)
Time Frame: 7 months
measurement of serum NT-proBNP level will be performed
7 months
Level of (cTnT)
Time Frame: 7 months
measurement of cTnT level will be performed
7 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sohag University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Anticipated)

January 15, 2023

Primary Completion (Anticipated)

June 30, 2023

Study Completion (Anticipated)

July 30, 2023

Study Registration Dates

First Submitted

December 23, 2022

First Submitted That Met QC Criteria

January 9, 2023

First Posted (Actual)

January 10, 2023

Study Record Updates

Last Update Posted (Actual)

January 12, 2023

Last Update Submitted That Met QC Criteria

January 11, 2023

Last Verified

January 1, 2023

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • Sohag_Med_22_12_07

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe